- Gallup: Take Care Clinics top in customer service
- The Little Clinic adds new insurance provider to accepted plans
- Bartell to cease filling Medicaid prescriptions at 15 locations
- CVS partnership may drive down healthcare costs
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
WOODCLIFF LAKE, N.J. The Food and Drug Administration has accepted for review a regulatory approval application for a patch made by Eisai to treat Alzheimer’s disease, the drug maker said Friday.
The agency will review a patch formulation of Aricept (donepezil hydrochloride), a weekly patch for treating mild, moderate and severe stages of the disease. The drug already is available in tablet form.
If the patch is approved, Eisai will have marketing rights in the United States and promote the patch under a partnership with Pfizer.